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ABSTRACT Gammaherpesviruses infect lymphocytes and cause lymphocytic cancers.
Murid herpesvirus-4 (MuHV-4), Epstein-Barr virus, and Kaposi’s sarcoma-associated her-
pesvirus all infect B cells. Latent infection can spread by B cell recirculation and prolifera-
tion, but whether this alone achieves systemic infection is unclear. To test the need of
MuHV-4 for lytic infection in B cells, we ﬂanked its essential ORF50 lytic transactiva-
tor with loxP sites and then infected mice expressing B cell-speciﬁc Cre (CD19-Cre).
The ﬂoxed virus replicated normally in Cre mice. In CD19-Cre mice, nasal and
lymph node infections were maintained; but there was little splenomegaly, and
splenic virus loads remained low. Cre-mediated removal of other essential lytic
genes gave a similar phenotype. CD19-Cre spleen infection by intraperitoneal virus
was also impaired. Therefore, MuHV-4 had to emerge lytically from B cells to colo-
nize the spleen. An important role for B cell lytic infection in host colonization is
consistent with the large CD8 T cell responses made to gammaherpesvirus lytic an-
tigens during infectious mononucleosis and suggests that vaccine-induced immunity
capable of suppressing B cell lytic infection might reduce long-term virus loads.
IMPORTANCE Gammaherpesviruses cause B cell cancers. Most models of host colo-
nization derive from cell cultures with continuous, virus-driven B cell proliferation.
However, vaccines based on these models have worked poorly. To test whether pro-
liferating B cells sufﬁce for host colonization, we inactivated the capacity of MuHV-4,
a gammaherpesvirus of mice, to reemerge from B cells. The modiﬁed virus was able
to colonize a ﬁrst wave of B cells in lymph nodes but spread poorly to B cells in sec-
ondary sites such as the spleen. Consequently, viral loads remained low. These re-
sults were consistent with virus-driven B cell proliferation exploiting normal host
pathways and thus having to transfer lytically to new B cells for new proliferation.
We conclude that viral lytic infection is a potential target to reduce B cell prolifera-
tion.
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Gammaherpesviruses infect lymphocytes, drive their proliferation, and predisposethem to transformation. Human gammaherpesviruses, for example, Epstein-Barr
virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), persist in B cells, as
does murine herpesvirus-4 (MuHV-4) (1), a murid gammaherpesvirus (2, 3). In vitro EBV
drives autonomous B cell proliferation. However, in vivo EBV-infected B cells show
evidence of passage through germinal centers (GC) (4), sites of T cell-dependent B cell
proliferation and transition to a resting memory state (5). MuHV-4 colonizes GC B cells
(6–8), and both EBV (9) and MuHV-4 (6, 7, 10) persist in memory-type B cells. Thus, GC
exploitation seems to be a common gammaherpesvirus theme. MuHV-4-infected B cell
proliferation depends on CD4 T cells (11), CD40 (12), BAFF receptor (13), and B cell
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major histocompatibility complex (MHC) class II expression (14), indicating close par-
allels with normal, antigen-driven proliferation. EBV host colonization also parallels
normal B cell physiology (15).
At steady state, most EBV-infected B cells express few viral antigens (9). Therefore,
to vaccinate against infection, it may be necessary to target earlier events. In EBV and
KSHV, these precede clinical presentation and remain ill deﬁned. For example, host
entry routes are unknown. Contact histories and acute tonsillitis led to a hypothesis of
oral acquisition for infectious mononucleosis (IM) (16). However, IM occurs at least a
month after EBV acquisition (17, 18) and matches peak host exit rather than entry.
Because infection is systemic, entry and exit need not occur at the same site.
In vitro, cell-free EBV can infect naive B cells, but all gammaherpesviruses also infect
non-B cells. If these are the primary targets, infection could reach B cells via antibody-
shielding cell-cell contacts. For EBV and MuHV-4, non-B cell infection involves antigeni-
cally distinct receptor binding events (19–21), and vaccination to block EBV binding to
B cells does not reduce in vivo infection rates (22). MuHV-4 enters new hosts nasally, not
orally (23), and ﬁrst infects olfactory epithelial cells (24). Herpes simplex virus 1 (25) and
murine cytomegalovirus (26) do so, too, implying that olfactory entry has been con-
served over hundreds of millions of years of herpesvirus evolution. MuHV-4 spreads
from the olfactory epithelium via infected dendritic cells (DC) and ﬁrst infects B cells in
the draining superﬁcial cervical lymph nodes (SCLN) (27). Infection increases in the
SCLN and then spreads to the spleen.
When mice lack B cells, SCLN infection remains modest, and splenic viral loads are
severely reduced (28, 29). Thus, MuHV-4 requires B cell infection for normal systemic
infection. For EBV, B cell infection is proposed to be sufﬁcient for the whole viral life
cycle (15). This would limit the opportunities for vaccine-induced immune control.
However, MuHV-4 shows additional complexity. When given intraperitoneally (i.p.), it
directly infects splenic marginal zone (MZ) macrophages and then spreads sequentially
to MZ B cells, follicular dendritic cells, and follicular B cells before colonizing splenic GC
(30), where there is B cell proliferation (8, 31). Intranasal (i.n.) MuHV-4 also reaches MZ
macrophages, and the presence of lytically infected plasma cells in SCLN (30) suggests
that spread to the spleen involves virion release into the efferent lymph. However,
memory B cell recirculation from the SCLN could be another route. While GC entry by
memory B cells has not been demonstrated in vivo (32, 33), some in vitro characteristics
of IgM memory B cells suggest that they might undergo further differentiation in GC
(34). To test the capacity of MuHV-4-infected B cells to colonize the spleen, we disabled
viral lytic infection in B cells. Thus, infection would be established in SCLN B cells but
then not spread to other cell types. Marked attenuation of splenic colonization argued
that infected memory B cells poorly enter new GC and supported the idea that host
colonization requires sequential lytic infections, making viral lytic antigens potentially
important vaccine targets.
RESULTS
B cell infection tracked by viral ﬂuorochrome switching. To track B cell infection,
we gave mice with B cell-speciﬁc Cre expression (CD19-Cre) i.n. MuHV-4 that carries a
ﬁtness-neutral expression cassette (21), switched by Cre from red to green ﬂuorescence
(MHV-RG) (Fig. 1a). By ﬂuorochrome typing recovered viruses, we could determine what
proportion had passed through a Cre cell. Many studies of MuHV-4 have inoculated
it into the lungs of anesthetized mice. We used a more natural upper respiratory tract
infection. Lytic infection here, which peaks at approximately day 7, is less extensive
than that in the lungs, making the kinetics of host colonization more protracted: nasal
infection reaches the spleen at day 11 to 14, with peak titers at day 21 to 25. At day 7,
MHV-RG recovered from noses showed 2% switching, so here B cells were not a
signiﬁcant target (Fig. 1b). In contrast MHV-RG recovered from SCLN showed 50%
switching. Therefore, B cells were ﬁrst infected in the SCLN. Spleens contained insuf-
ﬁcient virus to analyze switching at day 7, but at day 14 splenic virus was almost
completely switched.
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Sorting day 14 SCLN cells into B cells (CD19) and non-B cells (CD19) established
that MHV-RG in B cells was almost entirely switched. Virus recovered from non-B cells,
presumably myeloid cells (1), showed little switching, consistent with infection pro-
ceeding from olfactory epithelial cells (Cre) to myeloid cells (Cre) to B cells (Cre)
(27). In spleens both B cell and non-B cell viruses were switched, consistent with
infection spreading via SCLN B cells. However, because Cre-mediated recombination is
a single-hit process, we could not tell whether the splenic B cells had been infected in
the SCLN or in the spleen. Nor could we distinguish these possibilities in mice with
myeloid cell-speciﬁc Cre expression as MuHV-4 reaches the SCLN via myeloid cells and
so again is switched before reaching the spleen (21).
Conditional inactivation of MuHV-4 lytic infection. To deﬁne better how olfactory
infection reaches splenic B cells, we generated a virus in which Cre/lox recombination
inactivates lytic infection (Fig. 2). MuHV-4 initiates lytic infection via its ORF50 transac-
tivator: ORF50 mutants do not replicate without complementation (35) and when
inoculated i.n. do not reach the spleen (36). ORF50 MuHV-4 inoculated i.p. infects
splenic MZ macrophages but not B cells (30). This reﬂects splenic anatomy (MZ
macrophages ﬁlter the blood) and viral tropism (MuHV-4 must pass through myeloid
cells to gain B cell tropism) (21). ORF50 has two exons that span ORF49 (Fig. 2a). ORF49
encodes a tegument protein that interacts with ORF50 to promote lytic infection (37).
We inserted loxP sites between open reading frames (ORFs) 48 and 49 and between
ORFs 50 and M7 (MHV-F50), using an altered spacer region to make these sites
incompatible with the loxP sites ﬂanking the viral bacterial artiﬁcial chromosome (BAC)
cassette (38). Removal of ORF49 and ORF50 by virus passage through Cre cells was
conﬁrmed by PCR ampliﬁcation across this locus (Fig. 2b).
MHV-F50 was severely attenuated for replication in Cre ﬁbroblasts (Fig. 2c). Using
a derivative that expresses green ﬂuorescent protein (GFP) from an intergenic EF1
FIG 1 Cre/lox tracking of MuHV-4 spread from SCLN to spleens. (a) We used MuHV-4 with a color-
switching cassette inserted between ORFs 57 and 58 (MHV-RG). An ectopic viral M3 (lytic) promoter
drives expression of loxP-ﬂanked Cherry (red). Cre removes Cherry plus its polyadenylation site. The M3
promoter then drives expression of GFP (green). During host colonization each virus follows a chain of
infections, passing in CD19-Cre mice between Cre epithelial/myeloid cells (epi/M; shown as irregular
shapes) and Cre B cells (shown as round shapes). Passage through a Cre cell switches MHV-RG
irreversibly to GFP expression. (b) CD19-Cre mice were given MHV-RG i.n. to infect the upper respiratory
tract. After 7 to 14 days, titers for GFP and Cherry virus loads were determined by plaque assay (PFU)
or infectious center assay (i.c.) for noses, superﬁcial cervical LN (SCLN), and spleens. Virus switching was
calculated as follows: 100  GFP titer/(GFP titer  Cherry titer). Bars show means  standard errors
of the means of data for 6 mice. At day 14, SCLN and spleen cells, each pooled from 3 mice, were further
sorted into CD19 B cells and CD19 non-B cells before the color switching of recovered viruses was
determined (circles). d, day.
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FIG 2 Cre-dependent inactivation of MuHV-4 lytic infection. (a) To conditionally inactivate MuHV-4 lytic infection, we inserted loxP sites
between ORFs 48 and 49 and between ORFs 50 and M7 (MHV-F50). Thus, loxP recombination removed ORF49 and both exons of ORF50.
(b) To visualize this recombination, we infected 3T3-Cre cells (0.1 PFU/cell); 0, 5, and 8 days later we extracted DNA from the cultures and
performed PCR ampliﬁcation across ORFs 49 and 50 as indicated in panel a. UI, uninfected. The 3-kb band corresponds to the native,
unrecombined locus. The 0.5-kb band corresponds to the locus after recombination. (c) We compared wild-type (MHV-WT) and MHV-F50
growth in Cre (3T3-Cre) and Cre (3T3) ﬁbroblasts. Cells were infected (0.01 PFU/cell, 2 h), exposed to pH 3 to inactivate nonendocytosed
virions, washed in PBS, and cultured at 37°C. Virus titers in replicate cultures were determined by plaque assay daily thereafter. Each point
shows means  standard errors of the means of triplicate cultures. Time zero shows the virus input. (d) We infected 3T3-Cre cells with
GFP MHV-F50 and derived GFP cell clones. These were then stained for MuHV-4 lytic antigens with a polyclonal rabbit serum. Four
clones are shown at 5 weeks after cloning, in comparison with positive (infected 3T3 cell) and negative (uninfected 3T3 cell) controls. No
(Continued on next page)
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promoter independently of lytic infection (39), we established GFP-positive (GFP)
clones of virus-exposed Cre ﬁbroblasts that showed no lytic gene expression (Fig. 2d).
These clones showed some loss of GFP expression with continued culture (Fig. 2e), as
occurs also when MuHV-4 is kept latent by ORF50 transcriptional suppression (40).
Nonetheless, lytic infection could be initiated by transduction with an ORF50-positive
(ORF50) retrovirus (Fig. 2f), and the MHV-F50 recovered from cell supernatants could
then be propagated in ORF50-complementing ﬁbroblasts (Fig. 2g). It could not be
propagated in noncomplementing ﬁbroblasts. Therefore, MHV-F50 was inactivated for
lytic replication by Cre but was retained in a viable, latent form that could be recovered
by exogenous ORF50.
Early MHV-F50 infection in Cre mice. We gave MHV-F50 i.n. to CD19/Cre
(CD19-Cre) mice and CD19/ (wild type [WT]) littermate controls (Fig. 3). Typically,
nasal infection peaks at day 7, SCLN infection peaks at day 11, and splenic infection
peaks at day 20 to 30. At day 7 nasal virus titers were no different between WT and
CD19-Cre mice (Fig. 3a), consistent with the lack of MHV-RG switching in this site (Fig.
1b). At day 11, MHV-F50 SCLN infection in CD19-Cre mice was not signiﬁcantly less than
that in WT MuHV-4 or MHV-F50 infection in WT mice (Fig. 3b). At the same time point
MHV-F50 infection in CD19-Cre spleens was signiﬁcantly reduced.
SCLN infection has both myeloid and B cell components. The myeloid component
was expected to be normal. However, MHV-F50 B cell infection should have been
impaired in CD19-Cre mice, so it was surprising to see no signiﬁcant reduction in
recovery of replication-competent virus. This indicated a lack of recombination as
ORF50 loss completely prevents MuHV-4 lytic replication (35, 36), and PCR across the
ORF50 locus, as illustrated in Fig. 2b, conﬁrmed on multiple occasions that the
replication-competent MHV-F50 recovered from CD19-Cre SCLN was not recombined.
The most likely explanation was inefﬁcient excision of MHV-F50 ORF49 by Cre. We used
CD19/Cre mice, which express less Cre than CD19Cre/Cre mice (41) as CD19Cre/Cre mice
are CD19 deﬁcient (42); in addition, many infected B cells differentiate to plasma cells
(43), which downregulate CD19 (44). Thus, Cre expression was possibly low in some
infected B cells, and MHV-F50 attenuation must be considered only a minimum
estimate of the need for MuHV-4 to pass through B cells.
We assayed day 11 MHV-F50 infection also in CD11c-Cre (Fig. 3c) and LysM-Cre mice
(Fig. 3d). In a comparison of CD11c-Cre mice with littermate controls, MHV-F50 showed
a Cre-dependent defect in SCLN infection, consistent with MuHV-4 reaching the SCLN
via CD11c DC (27). However, there was no signiﬁcant defect in spleen infection. DC
infection is not uniformly lytic (45), so early (day 11) splenic infection may derive from
DC that rapidly produce new virus, while the infection still in SCLN at day 11 presum-
ably includes DC with slower virus production and thus longer exposure to Cre.
The normal SCLN infection and reduced splenic infection of LysM-Cre mice by
MHV-F50 was consistent with splenic infection proceeding via LysM MZ macrophages
(30).
Steady-state MHV-F50 infection in CD19-Cre mice. We then tracked MHV-F50 in
CD19-Cre mice up to day 35 (steady state) and compared the results with those of WT
mice given the same virus (Fig. 4). Colonization of CD19-Cre SCLN showed a signiﬁcant
defect at all time points after day 7. CD19-Cre spleens also showed signiﬁcant infection
FIG 2 Legend (Continued)
lytic antigen expression was evident in the cloned GFP Cre cells. (e) GFP expression of cell clones as illustrated in panel d was
determined by ﬂow cytometry during in vitro passage. GFP expression declined with time in all clones. Nonetheless, it was maintained
in a substantial proportion of cells, implying that recombined viral genomes were maintained. (f) After passage for 7 weeks, infected
3T3-Cre cell clones were transduced or not (control) with ORF50 retrovirus. Five days later they were stained for viral lytic antigens as
described for panel d. A representative example is shown. Not all lytic antigen-positive cells were GFP, suggesting that at least some of
the loss of viral GFP expression in the experiment shown in panel e was due to cassette silencing. No untransduced cells were lytic antigen
positive. (g) Supernatants of the retrovirus-transduced cultures in shown in panel f were used to infect NIH 3T3-ORF50 cells. Infection was
then identiﬁed by viral GFP expression. Three representative images are shown of plaques (clusters of 50 infected cells) developing 3
days after addition of cell supernatants. This rescue by exogenous ORF50 established that the recombined viral genomes maintained in
NIH 3T3-Cre cells were otherwise viable.
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defects at days 14, 23, and 35, with a signiﬁcantly greater defect after day 14 (Fig. 4a).
Thus, Cre-dependent MHV-F50 attenuation increased with time. The completeness of
viral genome recombination in individual B cells may increase with time. However,
latent viral genomes undergo chromatinization (46), which is associated with reduced
accessibility to Cre (47). Viral genomes are not chromatinized when they enter cells, so
this may be when they are most likely to be recombined by Cre. More recombination
with time would then be most likely to reﬂect additional passages through B cells.
Splenomegaly, which was most obvious in WT mice at day 23, was greatly reduced
in CD19-Cre mice (Fig. 4b). WT and CD19-Cre mice showed no obvious difference in the
degree of SCLN enlargement. MHV-F50 DNA loads were similar in WT and CD19-Cre
mice at day 14 and reduced in CD19-Cre mice thereafter, with spleens showing the
most marked differences (Fig. 4c). Sorting CD19 cells conﬁrmed that MHV-F50 ge-
nome loads were reduced in CD19-Cre B cells (Fig. 4d).
We visualized splenic infection by in situ hybridization for viral tRNA/miRNAs 1 to 4
(48) (Fig. 4e). In WT spleens, MHV-F50 showed positive signals in scattered cells at day
14 and strong GC signals at day 23. CD19-Cre spleens lacked detectable signals.
Therefore, by multiple measures MHV-F50 showed a marked splenic infection defect in
CD19-Cre mice.
FIG 3 Early lymphoid infection by MHV-F50. (a) We infected CD19-Cre mice or Cre littermate controls
(WT) i.n. with MHV-F50. Plaque assays showed no signiﬁcant difference in nose titers 7 days later. Bars
show means  standard errors of the means of titers of 6 mice per group. (b) WT or CD19-Cre mice were
given i.n. MHV-F50 or WT MuHV-4. Eleven days later virus titers in SCLN and spleens were determined
by infectious center (i.c.) assay. There was no difference in SCLN titers, but MHV-F50 titers were
signiﬁcantly reduced in CD19-Cre spleens. Bars show means  standard errors of the means of titers of
6 mice per group. (c) CD11c-Cre or WT mice were given i.n. MHV-F50. Eleven days later virus loads in
SCLN and spleens were determined by infectious center assay. F50 titers were signiﬁcantly reduced in
SCLN but not in spleens. Bars show means  standard errors of the means of titers of 6 mice per group.
(d) LysM-Cre mice were given i.n. MHV-F50 (F50) or WT MuHV-4 (WT). Eleven days later virus loads in
SCLN and spleens were determined by i.c. assay. MHV-F50 titers were equivalent to those of the WT in
SCLN and signiﬁcantly reduced in spleens. Bars show means  standard errors of the means of titers of
6 mice per group.
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FIG 4 Longer-term lymphoid infection by MHV-F50. (a) CD19-Cre mice or Cre littermate controls (WT) were given i.n. MHV-F50. Infectious center assays
recovered signiﬁcantly less virus from CD19-Cre SCLN and spleens from day 14 onwards. (b) For mice from the experiment shown in panel a, spleen weights
were signiﬁcantly lower in CD19-Cre mice. Bars show means  standard errors of the means of 6 mice per group. (c) The samples from the experiment shown
in panel a were assayed for viral genome load by quantitative PCR of puriﬁed DNA. CD19-Cre spleens yielded signiﬁcantly fewer viral genomes per cell at day
23 and day 35. (d) CD19-Cre and WT mice were infected with MHV-F50 as described for panel a, and at day 23 spleen cells were sorted into CD19 and CD19
subsets. Viral genome loads were assayed for each by quantitative PCR and were signiﬁcantly reduced in CD19-Cre mice. (e) CD19-Cre and WT mice were
infected as described for panel a. At day 14 and day 23, spleens were ﬁxed, and sections were probed for expression of viral tRNAs/miRNAs 1 to 4 by in situ
hybridization. Positive signals are shown in black. Sections were counterstained with hematoxylin (purple). The graph shows counts (means  standard errors
(Continued on next page)
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MuHV-4 inactivation by left-end genome excision. We also tested host coloni-
zation by MuHV-4 with loxP sites ﬂanking the left-hand 19 kb of its genome (MHV-F8/9)
(Fig. 4f). BAC-derived MuHV-4 retains a loxP site at the left end of its unique genome
sequence after BAC cassette excision (38). MHV-F8/9 has a compatible loxP site inserted
between ORF8 and ORF9 (27). The ﬂanked sequence includes ORFs 6 to 8, which are
essential for lytic infection, so again loxP recombination terminated viral spread to new
cells. Recombined MHV-F8/9 may also be impaired in latent genome survival as it loses
M1 to M4, viral tRNA/miRNAs 1 to 8, and a likely transcription start site for ORF73 (49).
This was not explored in detail as we wanted mainly to conﬁrm the Cre-dependent
attenuation of MHV-F50. At day 23 of i.n. infection, MHV-F8/9 showed no signiﬁcant
defect in SCLN infection of CD19-Cre mice but a signiﬁcant defect in spleen infection.
The MHV-F8/9 infection defect was less marked than that of MHV-F50, perhaps because
the 19-kb-spaced loxP sites of MHV-8/9 were less efﬁciently recombined than the
3-kb-spaced loxP sites of MHV-F50. Nonetheless, MHV-F8/9 infection was qualitatively
similar in being reduced mainly in the spleen.
Splenic infection by i.p. MHV-F50. B cells infected in the SCLN presumably
recirculate through the splenic MZ, but they were unable to colonize splenic GC. To test
whether MHV-F50 could colonize CD19-Cre spleens if SCLN B cells were bypassed, we
gave it i.p. (Fig. 5). MuHV-4 inoculated i.p. enters the spleen via MZ macrophages and
then passes sequentially to MZ B cells, follicular DC, and follicular B cells (30). Thus,
there is still a need to pass through B cells to reach GC. In MZ macrophages, i.p. MuHV-4
is mainly lytic; in follicular B cells it is mainly latent (29).
After i.p. inoculation, day 5 lytic infection showed only a small (10-fold) difference
in titers between the spleens of CD19-Cre mice and those of WT mice (Fig. 5a). This
result was consistent with MHV-F50 replicating normally in Cre MZ macrophages. At
day 5 of i.p. infection, most splenic infection is lytic, so the difference in total recov-
erable virus (lytic plus latent) was also small. At day 12 and day 21, when infection had
progressed to B cells (Cre) and was mostly latent, CD19-Cre mice showed a larger
(100-fold) reduction in total recoverable virus. Viral genome loads also showed a
larger defect at day 12 than at day 5 (Fig. 5a), so this was not just a difference in
reactivation; and CD19-Cre mice had signiﬁcantly less infection-driven splenomegaly
(Fig. 5b). These results were consistent with MHV-F50 passing poorly through Cre MZ
FIG 4 Legend (Continued)
of the means) of tRNA/miRNA-positive follicles for at least three sections from each of 3 mice per group. Representative images are shown. Arrows indicate
example positive cells. (f) We tested also MuHV-4 in which loxP sites ﬂank the unique left end of the viral genome from its start up to ORF9 (MHV-F8/9). This
allows Cre to remove the essential ORFs 6 to 8. We gave WT and CD19-Cre mice i.n. MHV-F8/9 and determined virus titers by infectious center assay at day
23. MHV-F8/9 showed somewhat less Cre-dependent attenuation than MHV-F50 but a similar pattern of reduced splenic rather than SCLN colonization.
FIG 5 Infection by i.p. inoculation with MHV-F50. (a) We gave CD19-Cre or WT mice MHV-F50 i.p. (105 PFU) and 5, 12, and 21 days later assayed preformed
infectious virus by plaque assay, total recoverable virus (preformed plus reactivation-competent latent virus) by infectious center assay, and viral genome
loads by quantitative PCR. Bars show titers (means  standard errors of the means) of 6 mice per group. ND, not detected. (b) Spleen weights of the
day 21 mice from the experiment shown in panel a showed signiﬁcantly less MHV-F50-driven splenomegaly in CD19-Cre mice than in WT controls. Bars
show titers (means  standard errors of the means) of 6 mice per group.
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B cells and thus poorly colonizing follicular B cells to generate GC. B cells infected in the
splenic MZ evidently failed to participate efﬁciently in GC formation.
DISCUSSION
The capacity of B cells for proliferation, longevity, and systemic migration makes
them a prime target for viral infections. GC exploitation allows gammaherpesviruses to
increase massively infected B cell numbers. This drives acute lymphadenopathy and
splenomegaly. The naive B cells that enter GC are segregated from mucosal surfaces:
they recirculate through lymph nodes (LN) and meet antigens only after they have
been captured by myeloid cells. MuHV-4 copes with this inaccessibility by infecting
myeloid cells. The compartmentalization of in vivo B cell populations further mandates
viral lytic replication for systemic spread as latently infected LN B cells poorly colonized
splenic GC.
Because B cells enter GC as naive cells and exit as memory cells, they cannot freely
cycle through multiple GC reactions. This applied also to MuHV-4-infected B cells. We
conclude that to exploit GC serially, gammaherpesviruses must transfer lytically from
memory back to new, naive B cells. An important role for lytic infection in B cell
colonization is consistent with the large acute CD8 T cell responses made to lytic
antigens during MuHV-4-induced (50) and EBV-induced IM (51). It explains why Blimp-1
deﬁciency, which impairs plasma cell differentiation and hence MuHV-4 reactivation,
impairs latency establishment (52). It may explain also why MuHV-4 lacking M2, which
promotes reactivation (53), poorly reaches splenic GC (54).
Upon MuHV-4 rechallenge of immune mice, splenomegaly does not recur. EBV-
driven IM also seems to occur just once. Thus, antiviral immunity limits GC colonization.
Analysis of EBV control has focused on recognizing viral latency gene products that
drive B cell proliferation in vitro. However, vaccination to prime such responses did
not reduce viral loads (55). T cell transfers reduce EBV-driven lymphoproliferation in
immunocompromised patients. However, they include CD4 and CD8 T cells with
multiple antigen speciﬁcities, and lytic antigen-speciﬁc CD4 T cells may be an impor-
tant component (56). CD8 T cell recognition of the M2 latency gene limits long-term
MuHV-4 loads (57), but priming this response gave no further reduction (58). Protection
against WT MuHV-4 by infection with latency-deﬁcient mutants (59–61) supports the
idea that immunity to lytic antigens can reduce latent viral loads. A need for lytic
infection to colonize GC would explain why. MuHV-4 reaches naive B cells via lytically
infected myeloid cells. CD4 T cells control myeloid infection; CD8 T cells control
epithelial infection well but control myeloid infection poorly due to viral evasion (62).
This may explain why priming lytic antigen-speciﬁc CD8 T cells failed to reduce latent
viral latent loads (63). Priming lytic antigen-speciﬁc CD4 T cells might be more
effective.
Gammaherpesvirus-driven splenomegaly is associated with generalized lymphade-
nopathy and with infection spreading to submucosal sites such as nasal-associated
lymphoid tissue (21). Thus, we envisage that systemic lymphoid colonization involves
multiple rounds of GC exploitation, with both LN-derived and spleen-derived memory
B cells seeding new naive B cell infections. Latent infection is then maintained despite
ongoing reactivation for transmission. Antigen-speciﬁc B cell memory does not suffer
from the same attrition, so homeostatic memory B cell proliferation alone seems
unlikely to maintain latent viral loads. Rather, new B cell infection and GC exploitation
must continue long-term. Consistent with this idea, MHV-F50 attenuation increased
with time. This would imply that the immune control of lymphoproliferation is incom-
plete, much as the control of virus shedding is incomplete. Nonetheless latency-
deﬁcient vaccines show that long-term lymphoid colonization can be kept to a very low
level.
A need for ongoing lytic infection to establish and maintain viral latent loads also
opens up the possibility of reducing latency with anti-lytic cycle drugs. Ganciclovir
reduces the risk of Kaposi’s sarcoma (KS) in AIDS (64). Inhibiting EBV lytic infection with
acyclovir has no obvious impact on IM (65). However, this report was based on a short
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course of treatment given when GC colonization was already at its height; when given
long-term, acyclovir reduces EBV latent loads (66). Other drugs more potently inhibit
EBV lytic infection (67). Their efﬁcacy will depend ultimately on the lytic turnover rate
of gammaherpesviruses, which is yet to be determined. The present data establish that
latency alone in B cells does not sufﬁce for host colonization, so lytic-based therapies
have the potential to limit latent infection.
MATERIALS AND METHODS
Mice. C57BL/6J, CD19-Cre (42), CD11c-Cre (68), and LysM-Cre mice (69) were kept at University of
Queensland animal units. The cre alleles were maintained by heterozygote  nontransgenic breeding.
Mice were given MuHV-4 (105 PFU) when 6 to 8 weeks old, either i.n. in 5 l without anesthesia to
inoculate the upper respiratory tract (70) or i.p. Animal experiments were approved by the University of
Queensland Animal Ethics Committees in accordance with Australian National Health and Medical
Research Council (NHMRC) guidelines. Statistical comparison was by heteroscedastic Student’s two-tailed
unpaired t test unless otherwise stated.
Cells and viruses. Baby hamster kidney (BHK-21) ﬁbroblasts (American Type Culture Collection
CCL-10), NIH 3T3 (CRL-1658), NIH 3T3-Cre (71), and NIH 3T3-ORF50 (23) cells were grown in Dulbecco’s
modiﬁed Eagle’s medium with 2 mM glutamine, 100 IU/ml penicillin, 100 g/ml streptomycin, and 10%
fetal calf serum (complete medium). MHV-GFP (39) expresses GFP from an EF1 promoter inserted
between the 3= ends of ORFs 57 and 58. MHV-RG (30) has in the same site an ectopic viral M3 (lytic)
promoter driving the transcription of loxP-ﬂanked mCherry plus a stop cassette upstream of GFP. Thus,
it forms mCherry-positive (mCherry) plaques (red) until recombined by Cre, when it switches to forming
GFP plaques (green). MHV-F8/9 (27) has a loxP site inserted at genomic coordinate 19055, between
ORFs 8 (glycoprotein B) and 9 (DNA polymerase). This can pair with a loxP site which remains at the left
end of the BAC-cloned viral genome between the terminal repeats and viral tRNA1 after the BAC cassette
is excised (38). Thus, loxP recombination by Cre deletes a 19-kb genomic segment that includes viral
tRNAs 1 to 8 and ORFs M1 to M4, 4, 6, 7, and 8. ORFs 6, 7, and 8 are essential to make infectious virions
(72). To prevent lytic cycle initiation, we inserted loxP sites around a 2.5-kb genomic segment incorpo-
rating ORF50 (MHV-F50). Its transcription initiates between ORFs 48 and 49 (73). We ampliﬁed by PCR
genomic coordinates 65100 to 66601, adding an SphI site at position 65100 and a loxP site at 66601. We
then ampliﬁed genomic coordinates 66602 to 68097, adding a loxP site at position 66602 and an SalI site
at 68097, just downstream of a genomic BstBI site (68088). The downstream primer also incorporated a
silent mutation in ORF50 at position 68084 to inhibit subsequent recombination of this segment by RecA
and thus promote the insertion of both loxP sites rather than just one. The 34-bp loxP site comprises 13
bp of complementary recognition regions, which are invariant, and an intervening 8-bp spacer region,
which can vary except for the central two bases. Cre recombines loxP sites only when their spacer regions
match. The loxP sites introduced around ORF50 had an altered spacer region (GGATACTT), making them
incompatible with those surrounding the viral BAC cassette (GCATACAT). The PCR products were gel
puriﬁed, denatured, mixed, annealed at their loxP sites, and reampliﬁed with the outer primers to
generate a 3-kb segment with a central loxP site at position 66601. This was cut with SphI and SalI and
ligated into the same sites of pSP73 (Promega) to make pSP73-loxP1.50. For the second loxP site, we PCR
ampliﬁed genomic coordinates 68080 to 69380, including a loxP site (again with spacer region GGATA
CTT) at 69380. A second PCR ampliﬁed the region of 69380 to 71000, incorporating a loxP site at position
69380 and SphI-XbaI sites at position 71000. Again, the two PCR products were gel puriﬁed, denatured,
mixed, annealed at their loxP sites, and reampliﬁed with the outer primers to give a 3-kb product with
a central loxP site. This was cut with BstBI-XbaI and ligated into psp73-loxP1, cut with the same enzymes
(BstBI site at the 3= end of 50.loxP1 and the XbaI site in psp73) to make pSP73-loxP1.50.loxP2. The
mutagenesis construct (consisting of the coordinates 65100 to 66601-loxP-66602 to 68084-silent
mutation-68085 to 69381-loxP-69382 to 71000) was excised with SphI, subcloned into the SphI site of
pST76K-SR, and recombined into the MuHV-4 BAC (38) to leave ORF49 (coordinates 66739 to 67644) and
ORF50 (66760 to 66795/67661 to 69376) ﬂanked by loxP sites at positions 66601 and 69381 (MHV-F50).
Viral genome integrity was checked by restriction enzyme digestion, and correct loxP site insertion was
checked by DNA sequencing across the insertion sites. In a further round of BAC mutagenesis, we
combined the F50 mutation with the MHV-GFP cassette (39) to make MHV-F50-GFP. BAC DNA was
reconstituted into infectious virus by transfection into BHK-21 cells (Fugene-6; Roche Diagnostics). The
ﬂoxed BAC/GFP cassette was removed by single passage through NIH 3T3-Cre cells (3 PFU/cell), followed
by plaque puriﬁcation of replication-competent, GFP-negative (GFP) virus. Stocks were prepared in
BHK-21 cells. Infected cell debris was removed by centrifugation (400  g, 5 min), and virions were then
recovered from supernatants by ultracentrifugation (38,000  g, 90 min).
Virus assays. To determine titers of infectious MuHV-4, culture-grown stocks or freeze-thawed organ
homogenates were plated on BHK-21 monolayers (74). To determine the titer of total reactivatable
MuHV-4, organs were disrupted into single-cell suspensions and then plated on BHK-21 cells. The cells
were cultured in complete medium for 3 h, overlaid with complete medium plus 0.3% carboxy-methyl-
cellulose, cultured for 4 days, ﬁxed with 1% formaldehyde, and stained with 0.1% toluidine blue for
plaque counting.
Immunoﬂuorescence. Cells were seeded onto glass coverslips and left to adhere (18 h at 37°C in
complete medium). For infection, MuHV-4 was added at the time of seeding (0.3 PFU/cell). The cells were
then ﬁxed in phosphate-buffered saline (PBS)–2% formaldehyde (30 min, 23°C), washed, and blocked in
PBS–2% bovine serum albumin (BSA)–0.1% Triton X-100 (30 min, 23°C). Viral antigens were detected with
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an MuHV-4-speciﬁc rabbit serum, raised by two subcutaneous inoculations of MuHV-4 virions (109 PFU).
The serum recognizes by Western blotting multiple virion proteins, including the products of ORFs 4, 65,
and M7 (75). The cells were washed three times in PBS–0.1% Tween 20. Antibody binding was detected
with Alexa 555-conjugated donkey anti-rabbit IgG polyclonal antibody (pAb) (Life Technologies). GFP
ﬂuorescence was visualized directly. Nuclei were stained with 4=,6=-diamidino-2-phenylindole (DAPI; 1
g/ml). After a further three washes, the cells were mounted in ProLong Gold (Invitrogen). Images were
acquired on a Nikon epiﬂuorescence microscope and analyzed with ImageJ.
Immunostaining. Organs were ﬁxed in 1% formaldehyde–10 mM sodium periodate–75 mM L-lysine
(18 h, 4°C), equilibrated in 30% sucrose (24 h, 4°C), and then frozen in 22-oxacalcitriol (OCT). Sections (6
m) were air dried (1 h, 23°C), washed three times in PBS, blocked with 0.3% Triton X-100–5% normal
donkey serum (1 h, 23°C), and incubated (18 h, 4°C) with combinations of antibodies to GFP (rabbit,
chicken, or goat pAb), CD11c (hamster monoclonal antibody [MAb] HL-3; BD Pharmingen), surfactant C
precursor (goat pAb) (Santa Cruz Biotechnology), olfactory marker protein (goat pAb; Wako Chemicals),
CD68 (rat MAb) (FA-11; AbCam), B220 (rat MAb RA3-6B2), CD169 (rat MAb 3D6.112) (Serotec), podoplanin
(goat pAb; R&D Systems), and MuHV-4 (rabbit pAb). tdTomato ﬂuorescence was visualized directly. After
samples were incubated with the primary antibodies, sections were washed three times in PBS,
incubated (1 h, 23°C) with combinations of Alexa 568-donkey anti-rat IgG pAb, Alexa 488- or Alexa
647-donkey anti-rabbit IgG pAb, Alexa 647-donkey anti-mouse IgM pAb, Alexa 488-donkey anti-chicken
IgG pAb (Abcam), and Alexa 488-donkey anti-goat pAb (Life Technologies); sections were then washed
three times in PBS, nuclei were stained with DAPI, and sections were mounted in Prolong Gold (Life
Technologies). tdTomato ﬂuorescence was visualized directly. Images were captured with a Zeiss LCM510
confocal microscope or a Nikon epiﬂuorescence microscope and analyzed with Zen imaging software or
ImageJ.
Viral genome quantitation. MuHV-4 genomic coordinates 24832 to 25071 were ampliﬁed by PCR
(Rotor Gene 3000; Corbett Research) from 10 ng of DNA (NucleoSpin tissue kit; Macherey-Nagel). PCR
products quantiﬁed with Sybr green (Invitrogen) were compared to a standard curve of cloned template
ampliﬁed in parallel and distinguished from paired primers by melting curve analysis. Correct sizing was
conﬁrmed by electrophoresis and ethidium bromide staining. Cellular DNA in the same samples was
quantiﬁed by amplifying a -actin gene fragment.
Flow cytometric sorting. Cells infected with GFP viruses were trypsinized, washed in PBS, and
analyzed directly for green channel ﬂuorescence on a BD Accuri 6 cytometer. For sorting, spleens were
disrupted into single-cell suspensions. Red cells and dead cells were removed by centrifugation on Ficoll.
The cells were washed in PBS–0.1% BSA, incubated (1 h, 4°C) with phycoerythrin-coupled anti-CD19
(BD-Pharmingen), washed two times, and ﬁltered (100-m pore size). CD19 cells were collected on a BD
FACSAria II and conﬁrmed to be 95% pure on reanalysis. DNA was extracted from the sorted cells for
viral genome quantitation.
In situ hybridization. Cells expressing viral tRNAs 1 to 4 were detected by in situ hybridization of
formalin-ﬁxed, parafﬁn-embedded spleen cell sections using a digoxigenin-labeled riboprobe (48).
Hybridized probe was detected with alkaline phosphatase-conjugated antidigoxigenin Fab fragments
(Boehringer Ingelheim).
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